Placebo improvement in pharmacologic treatment of menopausal hot flashes: Time course, duration, and predictors

Psychosomatic Medicine

Volumn 77, Issue 2, 2015, Pages 167-175

  Freeman, Ellen W ^a   Ensrud, Kristine E ^b,c   Larson, Joseph C ^d   Guthrie, Katherine A ^d   Carpenter, Janet S ^e   Joffe, Hadine ^f,g   Newton, Katherine M ^h   Sternfeld, Barbara ⁱ   LaCroix, Andrea Z ^j  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b Veterans Affairs Health System   (United States)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d Fred Hutchinson Cancer Research Center   (United States)

^e INDIANA UNIVERSITY   (United States)

^f BRIGHAM AND WOMEN S HOSPITAL   (United States)

^g HARVARD MEDICAL SCHOOL   (United States)

^h GROUP HEALTH RESEARCH INSTITUTE   (United States)

ⁱ DIVISION OF RESEARCH   (United States)

^j UNIVERSITY OF CALIFORNIA   (United States)

more..

Author keywords

hot flash treatment; menopause; placebo improvement; placebo response

Indexed keywords

ESCITALOPRAM; ESTRADIOL; PLACEBO; VENLAFAXINE; CITALOPRAM; SEROTONIN UPTAKE INHIBITOR;

ADULT; AFRICAN AMERICAN; ARTICLE; CLINICAL EVALUATION; CLINICAL FEATURE; CLINICAL TRIAL (TOPIC); CONTROLLED STUDY; DEMOGRAPHY; DISEASE SEVERITY; FEMALE; FOLLOW UP; HOT FLUSH; HUMAN; MAJOR CLINICAL STUDY; MENOPAUSE RELATED DISORDER; PLACEBO EFFECT; PREDICTIVE VALUE; PRIORITY JOURNAL; SCREENING; SMOKING; TREATMENT DURATION; TREATMENT OUTCOME; DOUBLE BLIND PROCEDURE; DRUG COMBINATION; HOT FLASHES; MIDDLE AGED; PSYCHOLOGY; RANDOMIZED CONTROLLED TRIAL;

CITALOPRAM; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRADIOL; FEMALE; HOT FLASHES; HUMANS; MIDDLE AGED; PLACEBO EFFECT; PLACEBOS; SEROTONIN UPTAKE INHIBITORS; TREATMENT OUTCOME;

EID: 84923478820     PISSN: 00333174     EISSN: 15347796     Source Type: Journal    
DOI: 10.1097/PSY.0000000000000143     Document Type: Article

References (32)

1. Khan A, Bhat A. Is the problem of a high placebo response unique to antidepressant trials? J Clin Psychiatry 2008;69: 1979-80.
2. Schweizer E, Rickels K. Placebo response in generalized anxiety: its effect on the outcome of clinical trials. J Clin Psychiatry 1997;58(suppl 11):30-8.
3. Roberts A. The powerful placebo revisited: implications for headache treatment and management. Headache Q 1994;5: 208-13.
4. MacLennanAH, Broadbent JL, Lester S,Moore V. Oral estrogen and combined oestrogen/progestogen therapy versus placebo for hot flushes. Cochrane Database Syst Rev 2004;CD002978.
5. Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B, Kimmick G, Lovato J, Gordon P, Pandya K, Guttuso T Jr., Barton D, Novotny P. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. J Clin Oncol 2009;27:2831-7.
6. Quitkin FM, Stewart JW, McGrath PJ, Nunes E, Ocepek-Welikson K, Tricamo E, Rabkin JG, Klein DF. Further evidence that a placebo response to antidepressants can be identified. Am H Psychiatry 1993;150:566-70.
7. Colloca L, Miller FG. Harnessing the placebo effect: the need for translational research. Phil Trans R Soc B 2011; 366:1922-30.
8. Rief W, Bingel U, Schedlowski M, Enck P. Mechanisms involved in placebo and nocebo responses and implications for drug trials. Clin Pharmacol Ther 2011;90:722-6.
9. Kam-Hansen S, Jakubowski M, Kelley JM, Kirch I, Hoaglin DC, Kaptchuk TJ, Burstein R. Altered placebo and drug labeling changes the outcome of episodic migraine attacks. Sci Transl Med 2014;6:218ra5.
10. Colloca L, Lopiano L, Lanotte M, Benedetti F. Overt versus covert treatment for pain, anxiety and Parkinson's disease. Lancet Neurol 2004;3:679-84.
11. Van DieMD, Bone KM, Burger HG, Teede HJ. Are we drawing the right conclusions from randomized placebo-controlled trials? A post-hoc analysis of data from a randomized controlled trial. BMC Med Res Methodol 2009;9:41.
12. Freeman EW, Guthrie KA, Caan B, Sternfeld B, Cohen LS, Joffe H, Carpenter JS, Anderson GL, Larson JC, Ensrud KE, Reed SD, Newton KM, Sherman S, Sammel MD, LaCroix AZ. Efficacy of escitalopram for hot flashes in healthy menopausal women. JAMA 2011;305:267-74.
13. Joffe H, Guthrie KA, LaCroix AZ, Reed SD, Ensrud KE, Manson JE, Newtown KM, Freeman EW, Anderson GL, Larson JC, Hunt J, Shifren J, Rexrode KM, Caan B, Sternfeld B, Carpenter JS, Cohen L. Low-dose estradiol and the serotonin-norepinephrine reuptake inhibitor venlafaxine for vasomotor symptoms a randomized clinical trial. JAMA Intern Med 2014;174:1058-66.
14. Newton KM, Carpenter JS, Guthrie KA, Anderson GL, Caan B, Cohen LS, Ensrud KE, Freeman EW, Joffe H, Sternfeld B, Reed SD, Sherman S, Sammel MD, Kroenke K, Larson JC, LaCroix AZ. Methods for the design of vasomotor symptom trials: the Menopausal Strategies: Finding Lasting Answers to Symptoms and Health network. Menopause 2014;21:45-58.
15. Pocock SJ, Simon R. Sequential treatment assignment with balancing for prognostic factors in the controlled clinical trial. Biometrics 1975;31:103-15.
16. Derogatis LR, Lipman RS, Rickels K, Uhlenhuth EH, Covi L. The Hopkins Symptom Checklist (HSCL): a selfreport symptom inventory. Behav Sci 1974;19:1-15.
17. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606-13.
18. Rutherford BR, Roose SP. A model of placebo response in antidepressant clinical trials. Am J Psychiatry 2013; 170:723-33.
19. Gold EB, Colvin A, Avis N, Bromberger J, Greendale GA, Powell L, Sternfeld B, Matthews K. Longitudinal analysis of the association between vasomotor symptoms and race/ ethnicity across the menopausal transition: Study of Women's Health Across the Nation. Am J Pub Health 2006;96: 1226-35.
20. Miller SR, Gallicchio LM, Lewis LM, Babus JK, Langenberg P, Zacur HA, Flaws JA. Association between race and hot flashes in midlife women. Maturitas 2006;54: 260-9.
21. Simpkins JW, Brown K, Bae S, Ratka A. Role of ethnicity in the expression of features of hot flashes. Maturitas 2009; 63:341-6.
22. Freeman EW, Sammel MD, Grisso JA, Battistini M, Garcia-Espagna B, Hollander L. Hot flashes in the late reproductive years: risk factors for African American and Caucasian women. J Womens Health 2001;10:67-76.
23. Butts SF, Freeman EW, Sammel MD, Queen K, Lin H, Rebbeck TR. Joint effects of smoking and gene variants involved in sex steroid metabolism on hot flashes in late reproductive-age women. J Clin Endocrinol Metab 2012; 97:E1032-42.
24. Gallicchio L, Miller SR, Visvanathan K, Lewis LM, Babus J, Zacur H, Flaws JA. Maturitas 2006;53:133-43.
25. Whiteman MK, Staropoli CA, Langenberg PW, McCarter RJ, Kjerulff KH, Flaws JA. Smoking, body mass and hot flashes in midlife women. Obstet Gynecol 2003;101:264-72.
26. Zhu BT, Conney AH. Functional role of estrogen metabolism in target cells: review and perspective. Carcinogenesis 1998; 19:1-27.
27. Scott DJ, Stohler CS, Egnatuk CM, Wang H, Koeppe RA, Zubieta JK. Placebo and nocebo effects are defined by opposite opioid and dopaminergic responses. Arch Gen Psychiatry 2008;65:220-31.
28. Meissner K, Bingel U, Colloca L, Wager TD, Watson A, Flaten MA. The placebo effect: advances from different methodological approaches. J Neurosci 2011;31:16117-24.
29. Fournier JC, DeRubeis RJ, Hollon SD, Dimijian S, Amsterdam JD, Shelton RC, Fawcett J. Antidepressant drug effects and depression severity: a patient-level metaanalysis. JAMA 2010;303:47-53.
30. Brown WA, Johnson MF, Chen MG. Clinical features of depressed patients who do and do not improve with placebo. Psychiatry Res 1992;41:203-14.
31. Freeman EW, SammelMD, Sanders RJ. Risk of long-term hot flashes after natural menopause: evidence from the Penn Ovarian Study Aging cohort. Menopause 2014;21:924-32.
32. Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, Hedayat S, Nikolic D, Krause EC, Pierson CE, Bolton JL, Pauli GF, Farnsworth NR. Safety and efficacy of black cohosh and red clover for themanagement of vasomotor symptoms: a randomized controlled trial. Menopause 2009; 16:1156-66.